iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with HR-positive, HER2-negative Early Breast Cancer By Ogkologos - November 14, 2024 917 0 Facebook Twitter Google+ Pinterest WhatsApp Final invasive disease-free survival results from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR What is Mindfulness? August 18, 2021 Two-Step Approach Might Be An Alternative to Standard Three-Step Approach of... December 6, 2022 The future of research: meet three of our scientists working on... December 13, 2022 EMA Recommends Extension of Indications for Serplulimab April 22, 2026 Load more HOT NEWS Clinical Trials in Genitourinary Cancers: MAGNITUDE, PROOF 302, and CYTOSHRINK Adding Pirtobrutinib to Venetoclax-Rituximab Shows Significant Improvement in PFS Among Patients... Liquid Biopsies for Cancer: What to Know and What to Expect Spirituality Resources
